



4970
7-6
Vc3
12.13-6
1614

TECH CENTER 1600/2900
MRI

DEC 10 2001

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Not Yet Assigned
Group : 1614
Applicant : Jochen Wolffgramm
Application No. : 09/851,817
Confirmation No. : 4970
Filed : May 9, 2001
For : USE OF AGONISTS OF THE
GLUCOCORTICOSTEROID AND/OR MINERALO-
CORTICOSTEROID RECEPTORS, IN
PARTICULAR CORTICOSTEROIDS FOR THE
TREATMENT OF ADDICTION

New York, New York
November 30, 2001

Hon. Commissioner for Patents
Washington, D.C. 20231

TRANSMITTAL LETTER FOR
INFORMATION DISCLOSURE STATEMENT

Sir:

Transmitted herewith is an Information
Disclosure Statement in the above-identified application.
This Statement is submitted:

within three months of the application filing date;
 more than three months from the application filing date but before the mailing date of the first Office Action on the merits.

In accordance with 37 C.F.R. § 1.97, submission of this Statement requires no fee. However, if for any reason a fee is due, the Director is hereby authorized to charge payment of any fees required in connection with

this Information Disclosure Statement to Deposit Account No. 06-1075. A duplicate copy of this letter is transmitted herewith.

Respectfully submitted,

Karen Mangasarian

James F. Haley, Jr. (Reg. No. 27,794)
Karen Mangasarian (Reg. No. 43,772)
Attorneys for Applicant
c/o FISH & NEAVE
1251 Avenue of the Americas
New York, New York 10020-1104
Tel.: (212) 596-9000

I Herby Certify that this
Correspondence is being
Deposited with the U.S.
Postal Service as First
Class Mail in an Envelope
Addressed to:
COMMISSIONER FOR
PATENTS
WASHINGTON, D.C. 20231 on

November 80, 2001
Lillian Garcia

Lillian Garcia
Signature of Person Signing

RECEIVED

DEC 10 2001

TECH CENTER 1600/2900
MREF 1



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Not Yet Assigned
Group : 1614
Applicant : Jochen Wolffgramm
Application No. : 09/851,817
Confirmation No. : 4970
Filed : May 9, 2001
For : USE OF AGONISTS OF THE
GLUCOCORTICOSTEROID AND/OR MINERALO-
CORTICOSTEROID RECEPTORS, IN
PARTICULAR CORTICOSTEROIDS FOR THE
TREATMENT OF ADDICTION

New York, New York
November 30, 2001

Hon. Commissioner for Patents
Washington, D.C. 20231

STATEMENT UNDER 37 C.F.R. §§ 1.97 AND 1.56

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(c),
applicant, through his attorneys, make of record the
following documents, copies of which are submitted
herewith*:

FOREIGN PATENT PUBLICATIONS

<u>Applicant</u>	<u>Publication No.</u>	<u>Publication Date</u>
Trustees of Boston University	WO 97/03677	February 6, 1997

* A completed Form PTO-1449 (in duplicate) listing
these documents is enclosed herewith.

OTHER DOCUMENTS

Albrecht, K. and Lampe, D. 1992. Diagnostik und Therapie von akuten Drogennotfällen. *Z. arztl. Fortbild.* 85, pp. 701-707.

Capasso, A. et al. 1995. Dexamethasone pretreatment reduces the psychomotor stimulant effects induced by cocaine and amphetamine in mice. *Prog. Neuropsychopharmacol. & Biol. Psychiat.* 19, pp. 1063-1079.

Capasso, A. et al. 1996. Dexamethasone selective inhibition of acute opioid physical dependence in isolated tissues. *J. Pharmacol. Exp. Therapeut.* 276, pp. 743-751.

Capasso, A. et al. 1997. Dexamethasone inhibition of acute opioid physical dependence in vitro is reverted by anti-lipocortin-1 and mimicked by anti-type II extracellular PLA₂ antibodies. *Life Sci.* 61, pp. 127-134.

Ehrenreich, H. et al. 1997. OLITA: an alternative in the treatment of therapy-resistant chronic alcoholics. *Eur. Arch Psychiatry Clin. Neurosci.* 247, pp. 51-54.

Mantsch, J.R. et al. 1998. Corticosterone facilitates the acquisition of cocaine self-administration in rats: opposite effects of the type II glucocorticoid receptor agonist dexamethasone. *J. Pharmacol. Exp. Therapeut.* 287, pp. 72-80.

Montgomery, S.P. and Dafny, N. 1987. Cyclophosphamide and cortisol reduce the severity of morphine withdrawal. *Int. J. Immunopharmacol.* 9, pp. 453-457.

Reddy, D.S. and Kulkarni, S.K. 1997. Neurosteroid coadministration prevents development of tolerance and augments recovery from benzodiazepine withdrawal anxiety and hyperactivity in mice. *Methods Find Exp Clin Pharmacol.* 19, pp. 395-405.

Sass, H. et al. 1996. Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence. *Arch. Gen. Psychiatry* 53, pp. 673-680.

Sze, P.Y. 1977. The permissive role of glucocorticoids in the development of ethanol dependence and tolerance. *J. Drug Alcohol Dep.* 2, pp. 381-396.

Whitworth, A.B. et al. 1996. Comparison of acamprosate and placebo in long-term treatment of alcohol dependence. *Lancet* 347, pp. 1438-1442.

CONCISE EXPLANATION OF NON-ENGLISH DOCUMENTS

Albrecht, K. and Lampe, D. describe diagnoses and therapies for acute drug emergencies (overdoses, or acute withdrawal symptoms), such as with amphetamines, cannabis, cocaine, opiates, and inhalants. A copy of an English translation is provided herewith.

None of the above-cited documents, made of record by applicant herein, renders unpatentable, either alone or in combination thereof, the pending claims of this statement.

Applicant request that these documents be (1) fully considered by the Examiner during the course of examination of this application; and (2) printed on any patent issuing from this application. Applicant also request that a copy of the enclosed Form PTO-1449, as considered and initialed by the Examiner, be forwarded to the undersigned with the next communication.

This statement is submitted more than three months from the application filing date but before the mailing date of the first substantive Office Action. In

accordance with 37 C.F.R. § 1.97, submission of this Statement requires no fee.

The Director, however, is hereby authorized to charge payment of any additional fee required in connection with this Information Disclosure Statement to Deposit Account No. 06-1075. A duplicate copy of this letter is transmitted herewith.

Respectfully submitted,

Karen Mangasarian

James F. Haley (Reg. No. 27,794)
Karen Mangasarian (Reg. No. 43,772)
Attorneys for Applicant
c/o FISH & NEAVE
1251 Avenue of the Americas
New York, New York 10020-1104
Tel.: (212) 596-9000

I Hereby Certify that this Correspondence is being Deposited with the U.S. Postal Service as First Class Mail in an Envelope Addressed to:
COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231 on

November 30, 2001
Lillian Garcia

Lillian Garcia
Signature of Person Signing